Junshi Biosciences’ Loqtorzi (Toripalimab) Receives the EC’s Approval for Treating Nasopharyngeal Carcinoma (NPC) and Esophageal Squamous Cell Carcinoma (ESCC)
Shots:
- The EC has approved Loqtorzi as a 1L treatment of recurrent or metastatic NPC as well as in addition to cisplatin & paclitaxel for advanced ESCC, valid in all EU plus Iceland, Norway & Liechtenstein
- Approval in NPC was based on P-III (JUPITER-02) study of Loqtorzi + CT vs PBO, showing 48% reduction in disease progression & a 37% reduction in death risk and mPFS extended by 13.2mos. with a 5yrs. survival rate of 52%; attained higher ORR, DoR & DCR
- Approval in ESCC was based on P-III (JUPITER-06) study of Loqtorzi + paclitaxel & cisplatin vs PBO, showing superior PFS & OS, with extended mOS from 6mos. to 17mos., reduced disease progression or death risk by 42% and a consistent survival benefit regardless of PD-L1 status
Ref: Globenewswire | Image: Junshi Biosciences
Related News:- Junshi Biosciences Reports the CHMP’s Positive Opinion of Loqtorzi (Toripalimab) Across Two Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
